Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Healthcare Biotechnology
Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSXV:HEM)

Hemostemix Announces Engagement of Oak Hill Asset Management Inc.

Newsfile March 7, 2024

Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences

Newsfile February 6, 2024

Hemostemix Clarifies its October 3, 2023 News Release

Newsfile December 29, 2023

Hemostemix's 4th Heart Study Published in Stem Cell Research & Therapy Confirms Breakthrough Treatment for Heart Disease

Newsfile October 30, 2023

Hemostemix Announces Amendment of its $2.5 Million 5 Year Convertible Debenture Issued on June 11, 2021, Resulting in an Expected Interest Saving of Approximately $570,000

Newsfile October 23, 2023

Hemostemix Closed $320,125 Private Placement

Newsfile October 3, 2023

Hemostemix Announces Private Placement

Newsfile September 27, 2023

Hemostemix Announces New Publication: How NCP-01 Supports Brain Computer Interfaces

Newsfile September 12, 2023

Hemostemix Announces the Incorporation of Hemostemix Quebec Inc. and $6 Million in Grant Applications

Newsfile August 29, 2023
View More News ››

Opinion & Analysis (TSXV:HEM)

Shaping the Future of Regenerative Medicine Today

Dave Jackson February 11, 2021

Hemostemix Founder: A Man with a Compassionate Heart

Featured Submission December 15, 2020

Shaping the Future of Medicine by Delivering Regenerative Medicines

Dave Jackson December 9, 2020
View More Opinion ››

Bullboard Posts (TSXV:HEM)

RE:Ah, what will the New Year bring?

Dude, I'm in the same boat. Will a government grant save the day on the very last minute? Indeed 2024 will tell.
JocetooBad - February 16, 2024

Ah, what will the New Year bring?

2024 will either be HEM's last year, or else one of their many claims actually proves to have substance.  Thomas has drained his...
Dudeforever - December 7, 2023

RE:$HEM experience is very bad

Same person, multiple new accounts, and all of them full of negativity, designed to try and get people to sell.  I was waiting for...
Budaman - October 31, 2023

$HEM experience is very bad

The company's financial statements show declining revenue; the company is not keeping up with industry trends. In my experience, this...
Gefele1424 - October 31, 2023

Dark Days for $HEM: Shareholders Left Empty-Handed as Stock

$HEM's stock as a beacon of hope now themselves in the dark as the company's fortunes crumble. The market value of $HEM's...
hexekay - October 31, 2023

$HEM's Stock Fails to Deliver as Services Struggle.

$HEM's stock, which was once a beacon of hope among penny stocks, has lost its shine as the company's services falter, causing a...
Williammax - October 31, 2023
View more Bullboard ››

Revive Therapeutics Ltd.

Revive Therapeutics Ltd.

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of ...
View More »